Women frequently have more easily overlooked symptoms of ADHD, leading many to go undiagnosed or misdiagnosed until adulthood.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

A novel triple reuptake inhibitor is efficacious and ‘clinically meaningful’ for adult attention-deficit/hyperactivity ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

See Supernus Pharmaceuticals, Inc. (SUPN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Get the latest news and real-time alerts from Supernus Pharmaceuticals, Inc. (SUPN) stock at Seeking Alpha. Skip to content Home page Seeking Alpha - Power to Investors ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers. The branded pharmaceutical industry relies on a ...

Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of radiographic progression or death when combined with androgen deprivation ...